Physician profile
Swapnil Patel
NPI 1881127975
$442.67
in general payments reported to CMS, 2019-2025
15 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.97 · 2022: $98.55 · 2023: $107 · 2024: $109 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $332.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $97.84 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $57.01 | 2021-2022 | |
| Exact Sciences Corporation | $47.43 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $39.55 | 2023-2024 | |
| Abbvie INC. | $34.17 | 2023-2025 | |
| Shionogi INC | $21.51 | 2022 | |
| Dynavax Technologies Corporation | $18.89 | 2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $17.45 | 2024 | |
| Sanofi-Aventis U.S. LLC | $17.37 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.85 | 2023 | Saphnelo |
| Novo Nordisk INC | $16.17 | 2024 | Wegovy |
| Dexcom, INC. | $15.80 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $14.53 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $14.19 | 2024 | Gvoke Hypopen |
| Medtronic, INC. | $13.91 | 2024 | Closurefast |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swapnil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.